Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived mesenchymal stem cells for knee osteoarthritis
ACTRN12614000814673Phase 2Completed
- Sponsor
- Magellan Stem Cells
- Start
- Sep 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in osteoarthritis (OA) and knee osteoarthritis (OA) (3 arms), sponsored by Magellan Stem Cells. Primary endpoints: Knee Injury and Osteoarthritis Outcome Score, Numerical Pain Rating Scale and 1 more. Started Sep 2014; status: completed.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
osteoarthritis (OA)knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12614000814673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000814673.